CIRB Approval of Recruitment/Patient Education Materials

Date: October 19, 2021

Study ID: S2013

Study Title: Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study

Study Chair: Krishna Gunturu, MD

The NCI Cancer Prevention and Control CIRB reviewed S2013 Participant Materials (version 09/30/21) on October 19, 2021 and granted approval. The expedited review was conducted in accordance with the Federally-defined categories of expedited review stated in 45 CFR 46.110(b)(1)(ii) and 21 CFR 56.110(b)(2).

The following documents were reviewed:

1. CIRB Application (PVD 07/21/21)
2. Plain Language Summary (version 09/30/21)
3. Tweets and Graphics (version 09/30/21)

As the Study Chair, you are responsible for reporting all study-related activity and correspondence to the CIRB.


If you have any questions regarding this review, please contact the Cancer Prevention and Control CIRB Coordinator at cpccirb@emmes.com.

cc: Mariah Norman,
Diane St. Germain, MS, RN
Lori Minasian, MD, FACP
Linda Parreco, RN, MS
Crystal Miwa
CTSU Protocol Westat
Dana Sparks
Dawn Hershman, MD, BA, MS
Joseph Unger, PhD